Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing safety and effectiveness of BESREMi in Japanese patients with polycythemia vera
jRCT2031240088Recruiting
- Sponsor
- PharmaEssentia
- Start
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of ropeginterferon alfa-2b in polycythemia vera (PV), sponsored by PharmaEssentia. Primary endpoints: Safety – overall adverse events, Safety – events by patient background and 1 more. Started Apr 2024; status: recruiting.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on jRCT2031240088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240088.